An independent data monitoring committee assessed that the PRECISION1 trial of nab-sirolimus in solid tumors would not meet an efficacy threshold to support the agent’s accelerated approval. The phase 2 PRECISION1 trial (NCT05103358) evaluating nab-sirolimus (Fyarro) in patients with solid tumors harboring TSC1 or TSC2 inactivating alterations will be...

Phase 2 Trial of Nab-Sirolimus in Solid Tumors Stops Due to Futility

Two separate clinical trials have found that a class of drugs that stymie inflammation may improve the effectiveness of commonly used immunotherapies. In both trials—one involving people with lung cancer and the other with lymphoma—adding a JAK inhibitor to an immune checkpoint inhibitor shrank tumors in more than half of the participants.

Drug Combo JAKs Up Immunotherapy in Two Clinical Trials

In an Indian phase II trial (BEER BTC) reported in the Journal of Clinical Oncology, Ramaswamy et al found that maintenance therapy with bevacizumab/erlotinib improved progression-free survival vs active surveillance in patients with advanced biliary tract cancers who had at least stable disease after gemcitabine-based chemotherapy. As stated by the...

Advanced Biliary Tract Cancers: Bevacizumab/Erlotinib Maintenance vs Active Surveillance

Adrienne Waks, MD, discusses the unmet needs in early-stage HER2-positive breast cancer. The DAPHNe trial (NCT03716180) investigated the prevalence and dynamics of circulating tumor DNA (ctDNA) in patients with early-stage HER2-positive breast cancer undergoing neoadjuvant therapy. In the study, 92% of patients had detectable ctDNA at baseline, suggesting widespread minimal...

Navigating Treatment Options for HER2+ BC: A Need for Customization

Researchers have demonstrated that adding metastasis-directed radiation therapy to standard-of-care chemotherapy may improve progression-free survival in patients with oligometastatic pancreatic cancer, according to a recent study published by Ludmir et al in the Journal of Clinical Oncology and previously presented at the 2024 ASCO Gastrointestinal Cancers Symposium (Abstract 603). Background.

Metastasis-Directed Radiation Therapy Plus Chemotherapy in Oligometastatic Pancreatic Cancer

In 2024, kidney cancer is projected to be one of the top 10 cancers in terms of incidence rate in the United States, with an estimated 81,610 new diagnoses. In 2024, kidney cancer is projected to be one of the top 10 cancers in terms of incidence rate in the United States, with an estimated 81,610 new diagnoses.1 with an estimated 81,610 new diagnoses. Renal cell carcinoma (RCC) accounts for approximately 80% to 90% of all kidney cancer cases, with the predominant subtype being clear cell RCC (ccRCC).2.

From Bench to Bedside: HIF-2α Inhibition in RCC

Reuters

(Reuters) -Trial results show Eli Lilly's weight loss drug Zepbound reduces the risk of hospitalization, death and other outcomes for obese adults with a common type of heart failure, the company said on Thursday as it continues to build a case for the medication's wider health benefits.

Lilly says weight loss drug cuts heart failure risk by 38% in trial

Interesting Engineering

Patients experienced a significant reduction in pain, improved their quality of life, and even showed signs of cartilage regrowth.

Stem cell shot reverses osteoarthritis, repairs knee cartilage, cuts pain by 58%

First-line amivantamab plus lazertinib has been approved by the FDA for locally advanced or metastatic EGFR-mutated non–small cell lung cancer. The FDA approved first-linen amivantamab-vmjw (Rybrevant) plus lazertinib (Lazcluze) to treat adult patients with locally advanced or metastatic non–small cell lung cancer (NSCLC) harboring EGFR exon 19 deletions or exon 21 L858R substitution mutations.1.

First-Line Amivantamab Plus Lazertinib Receives FDA Approval for EGFR-Positive Advanced NSCLC

Toni English’s medical team was giddy. It was six weeks after English had completed an experimental cancer treatment, and she had arrived at the Orlando Health Cancer Institute in Florida with her husband to see the results of her latest scan. Her team gathered in a patient exam room...

A newly approved ‘living drug’ could save more cancer patients’ lives

SurvivorNet

A rare form of endometrial cancer - uterine serous carcinoma – is more aggressive in Black women compared to white women, according to a new study published in the medical journal Proceedings of the National Academy of Sciences.

As Howard Stern’s Sidekick Robin Quivers, 71, Embraces ‘Bald Hairdo’ Amid Endometrial Cancer, New Study Finds a Rare Form of the Cancer Is More Aggressive In Black Women

Acute Monoblastic Leukemia is a rare but aggressive type of cancer affecting the blood and bone marrow. It primarily involves monoblasts, which are immature white blood cells. This disease progresses rapidly, requiring prompt diagnosis and treatment. Symptoms often include fatigue, fever, and frequent infections. Risk factors can range from genetic predispositions to previous chemotherapy treatments. Understanding this condition is crucial for early intervention and better outcomes. In this post, we'll explore 20 essential facts about Acute Monoblastic Leukemia, shedding light on its causes, symptoms, treatments, and more. Stay informed to better recognize and combat this challenging disease.

20 Facts About Acute Monoblastic Leukemia

The combination of Opdivo plus Yervoy is already established as a second-line treatment for patients with advanced hepatocellular carcinoma. A press release from Bristol Myers Squibb on Aug. 21, 2024 announced that two of its products, Opdivo (nivolumab) plus Yervoy (ipilimumab), were accepted in tandem with one another as a potential first-line treatment for adult patients with unresectable hepatocellular carcinoma (HCC). FDA has accepted the company’s supplemental Biologics License Application based on results from a Phase III trial (CheckMate -9DW), and set a Prescription Drug User Fee Act goal date of Apr. 21, 2025 (1).

Bristol Myers Squibb Application for Unresectable Hepatocellular Carcinoma First-Line Treatment Accepted by FDA

The following is a summary of “CD4+CD8αlow T cells in rheumatoid arthritis are clonally expanded and dependent on co-stimulation,” published in the July 2024 issue of Rheumatology by Beck et al. CD4+CD8+ T cells, elevated in patients with rheumatoid arthritis (RA), are linked to joint erosions and...

CD4+CD8+ T Cell Clonality and Treatment Response in RA Using Single-Cell Sequencing

(Reuters) -The U.S. Food and Drug Administration on Tuesday approved Johnson & Johnson's chemotherapy-free combination treatment for a type of non-small cell lung cancer, setting up a challenge for AstraZeneca's blockbuster drug Tagrisso.

J&J's chemotherapy-free treatment for lung cancer gets US approval

Non smoker diagnosed Wirth lung cancer and EGFR medications used

Dismissed By Doctors, Distance Runner Mom, 43, Diagnosed With Lung Cancer– She Never Smoked

University of Queensland research could lead to a more effective immunotherapy treatment against bladder cancer. A team led by Associate Professor Fernando Guimaraes from UQ’s Frazer Institute has found the mechanism used by bladder cancer to suppress the immune system’s natural killer (NK) cells. “We found that cancer...

Potential Immunotherapy Treatment Pathway for Bladder Cancer Identified

Combination therapy with ezetimibe led to a greater reduction in LDL-C levels than statin monotherapy, but no significant effect on MACE outcomes. Adding ezetimibe to low- or moderate-intensity statins led to a higher reduction in low-density lipoprotein cholesterol (LDL-C) than high-intensity statin monotherapy in patients with existing atherosclerotic cardiovascular disease (ASCVD), according to the results of a systematic review and meta-analysis.1.

Combination Ezetimibe, Statin Therapy Superior in Reducing LDL-C Levels

Cancer Health

In 2006, Diana Lindsay, who had never so much as held a cigarette, was diagnosed with stage 4 lung cancer. It had metastasized to both lungs, her brain and lymph nodes. Keith Eaton, MD, PhD, clinical director of thoracic, head and neck medical oncology at Fred Hutch Cancer Center, told her that a typical patient in this situation would have about nine months to live. But he also observed that she seemed remarkably strong and vital. “He said, ‘You don’t look like my normal lung cancer patient,’” said Lindsay, who had just returned from a business trip to Europe. She was 54 at the time. “He didn’t want to take away the health I had for the limited time I had to live.”

20 Years Since an EGFR Discovery, a Woman With Stage IV Lung Cancer Is Thriving

The Independent

 A new vaccine that primes the immune system to recognise and fight lung cancer is being tested for the first time on patients in the UK.Researchers leading the trial said the treatment could improve survival rates among people with the disease, with hopes that it could eventually become the standard of care worldwide.Known as BNT116 and made by BioNTech, the vaccine is designed to treat non-small cell lung cancer (NSCLC), the most common form of the disease.It utilises messenger RNA (mRNA), similar to Covid-19 vaccines, and works by presenting the immune system with tumour markers from NSCLC to prime...

Lung cancer vaccine tested on UK patient for the first time

NewsBreak

Long-Term Immune Checkpoint Inhibition Shows Potential Extended Survival in NSCLC

Biagio Ricciuti, MD, discussed findings from a retrospective study exploring the use of immune checkpoint inhibitors for longer than 2 years in patients with non–small cell...

Long-Term Immune Checkpoint Inhibition Shows Potential Extended Survival in NSCLC

Comments / 0